Close

Biotinylated Human FAP CAR Detection Reagent, His,Avitag™ (CARD-LX161)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Evaluating CAR expression is an essential step in the production of CAR-T cells. Creative biolabs provides several detection reagents which are uniquely suitable for evaluation of CAR expression. Biotinylated Human FAP CAR Detection Reagent, His,Avitag™ is a special detection reagent which is used to detect Human FAP CAR related to the study of colon cancer.

Specific Inquiry

  • Size:
  • Form:
  Add to Cart

Specifications

  • Target
  • FAP
  • Application
  • FC, ELISA
  • Purity
  • >90%
  • Endotoxin Level
  • Less than 1.0 EU per μg by the LAL method.
  • Storage
  • For long term storage, the product should be stored at lyophilized state at -20°C or lower.
    Please protect from light and avoid repeated freeze-thaw cycles.
  • Application Notes
  • The optimal working dilutions should be determined by the end user.
  • Diseases
  • colon cancer
  • Molecular Characterization
  • It contains AA Leu 26 - Asp 760 (Accession # Q12884-1).
  • Conjugation
  • Biotinylated
  • Size
  • 200ug
  • Formulation
  • Lyophilized from 0.22 μm filtered solution in 20 mM Tris, 150 mM Potassium glutamate, pH7.5. Normally trehalose is added as protectant before lyophilization.
  • Expression
  • Human HEK293 cells
  • Host Species
  • Human
  • Species Reactivity
  • Human
  • Form
  • lyophilized
  • Images
  • Figure 1 Structure

Target

  • Target Introduction
  • FAP (also known as seprase) is a Type II transmembrane serine protease. Both plasma membrane and soluble forms exhibit post-proline cleaving endopeptidase activity, with a marked preference for Ala/Ser-Gly-Pro-Ser/Asn/Ala consensus sequences. Degrade also gelatin, heat-denatured type I collagen. Also has dipeptidyl peptidase activity, with a preference for Ala-Pro, Ile-Pro, Gly-Pro, Arg-Pro and Pro-Pro. The plasma membrane form, in association with either DPP4, PLAUR or integrins, is involved in the pericellular proteolysis of the extracellular matrix (ECM), and hence promotes cell adhesion, migration and invasion through the ECM. Promotes glioma cell invasion through the brain parenchyma by degrading the proteoglycan brevican. Acts as a tumor suppressor in melanocytic cells through regulation of cell proliferation and survival in a serine protease activity-independent manner.
  • Target Alternative Names
  • FAP

Customer Reviews and Q&As

There are currently no customer reviews or questions for Biotinylated Human FAP CAR Detection Reagent, His,Avitag™ (CARD-LX161). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.